AMRX enters this week's session caught between a fresh analyst upgrade and a stock that has shed 15% in a month — a gap that defines the current setup for Amneal Pharmaceuticals.
Options positioning is the most charged signal right now. The put/call ratio jumped to 1.10 on Tuesday, more than two standard deviations above its 20-day average of 0.54 — a level consistent with heavy demand for downside protection. That shift is abrupt. For most of April and early May the PCR ran well below 0.40, close to the bullish end of its range. The pivot toward defensive positioning coincides almost exactly with the Q1 earnings release on May 7, which produced a 3% next-day drop and a further 10% drawdown over the following five sessions.
Short interest tells a more complicated story. Bears have been building since late April — SI as a percentage of free float has risen from roughly 2.2% in mid-April to 4.0% as of May 19, an 80% jump over 30 days. Most of that move happened in a single step around May 11, when shares short jumped from about 9.4 million to 13.5 million. Yet the borrow market is far from stressed: cost to borrow is running near 0.44% APR — low by any measure — and availability is vast relative to current short demand, with the ratio of available shares to short interest at roughly 1,900%. There is no sign of a supply squeeze underpinning the short build; this looks like a deliberate directional trade rather than any structural tightness.
The Street, however, is pulling in the opposite direction. This morning Barclays raised its price target on AMRX from $15 to $16 while maintaining its Overweight rating — a fresh signal from a bellwether firm filed just hours before this note. The consensus mean target sits at $17.20 against a current price of $11.81, implying roughly 46% return potential to the average bull case. That gap has widened as the stock has sold off; the PE has compressed to about 11x and the EV/EBITDA multiple is near 8x. UBS initiated with a Buy and a $19 target back in April. The factor score picture is mixed: EPS momentum over 90 days ranks in the 73rd percentile and the dividend score at the 73rd, but forward EPS growth expectations are weak at only the 19th percentile, and the analyst-consensus differential score sits near the bottom decile, reflecting the disconnect between bullish ratings and subdued underlying growth forecasts.
Ownership context adds nuance. The Patel family — Chintu, Chirag and Dipan collectively control around 20% of shares — continues to hold. BlackRock added a significant 10.2 million shares in the period to April 30, taking its stake to 7.7% of the company. State Street similarly added 2.7 million shares. Those institutional inflows give weight to the analyst bulls, though Rubric Capital trimmed by 1.3 million shares over the same period, the most notable active-manager exit in the table. On the insider side, only one cash trade stands out: independent director Deborah Autor sold 34,819 shares at $12.94 on May 11, pocketing just over $450,000. That came on the same day the short-interest build accelerated, though the transaction is too small to read as a directional signal.
Earnings reaction data points to a Q2 date of August 7. The last two prints produced a sharp divergence: the Q1 result (reported May 7) produced a 3% day-one drop and a 10% five-day slide, while Q4 2025 generated a modest one-day gain before also fading over a week. The pattern is not consistent, but the May earnings report has clearly reset sentiment downward into a trading range the stock has not held for several months. Closer peers confirm the generalised sector pressure: ELAN fell 7.6% on the week and VTRS dropped 5.8%, while AMPH held up better at nearly flat — the sell-off in AMRX is real but not entirely idiosyncratic.
With the next earnings date two and a half months away, the key near-term variable is whether the fresh Barclays target raise — and the still-wide gap between price and consensus targets — is enough to arrest a stock that options markets have turned cautious on at exactly the same moment short sellers ramped their positions.
See the live data behind this article on ORTEX.
Open AMRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
